Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $18.63 Consensus PT from Analysts

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has earned a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $18.6250.

Several research analysts have recently commented on LXEO shares. Leerink Partners raised their price objective on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. HC Wainwright restated a “buy” rating on shares of Lexeo Therapeutics in a research note on Monday, November 3rd. Cantor Fitzgerald initiated coverage on Lexeo Therapeutics in a research note on Monday, December 1st. They issued an “overweight” rating and a $19.00 price objective on the stock. Chardan Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a report on Wednesday, November 5th. Finally, Guggenheim started coverage on Lexeo Therapeutics in a report on Wednesday, October 15th. They set a “buy” rating and a $30.00 price target on the stock.

Insider Buying and Selling

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 13,133 shares of the business’s stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $8.94, for a total transaction of $117,409.02. Following the completion of the transaction, the chief executive officer owned 242,118 shares in the company, valued at $2,164,534.92. The trade was a 5.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Eric Adler sold 3,382 shares of the stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $8.94, for a total transaction of $30,235.08. Following the completion of the sale, the insider directly owned 73,261 shares in the company, valued at approximately $654,953.34. This represents a 4.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 24,646 shares of company stock worth $221,037. Company insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Lexeo Therapeutics

Institutional investors have recently modified their holdings of the company. CWM LLC grew its stake in shares of Lexeo Therapeutics by 150.3% during the second quarter. CWM LLC now owns 10,351 shares of the company’s stock worth $42,000 after purchasing an additional 6,216 shares in the last quarter. Ethic Inc. acquired a new stake in Lexeo Therapeutics in the second quarter valued at $44,000. Cerity Partners LLC purchased a new stake in Lexeo Therapeutics during the 2nd quarter worth about $50,000. Intech Investment Management LLC boosted its position in shares of Lexeo Therapeutics by 20.7% during the 2nd quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock worth $55,000 after acquiring an additional 2,342 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Lexeo Therapeutics during the 2nd quarter worth about $60,000. 60.67% of the stock is owned by hedge funds and other institutional investors.

Lexeo Therapeutics Trading Up 2.9%

Shares of NASDAQ LXEO opened at $9.35 on Wednesday. The stock has a market capitalization of $682.46 million, a PE ratio of -3.46 and a beta of 1.76. Lexeo Therapeutics has a twelve month low of $1.45 and a twelve month high of $10.38. The stock has a fifty day simple moving average of $8.76 and a 200-day simple moving average of $5.92.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.15. On average, equities analysts predict that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.